Erythropoietin: a new perspective in cardiovascular therapy

Raddino, Riccardo; Robba, Debora; Caretta, Giorgio; Bonadei, Ivano; Teli, Melissa; Zanini, Gregoriana; Madureri, Alberto; Vizzardi, Enrico; Dei, Livio

doi:10.4081/monaldi.2008.414

Cited by 5 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of its significant biological functions, recombinant human erythropoietin (rhEPO) was first hematopoietic growth factor to be cloned[5] and has been extensively used as pharmaceutical product for the treatment of anemia in chronic kidney disease, cancer chemotherapy and many other diseases[6], ever since it first became available as a drug in 1988[7]. Moreover, it is well-known for its misuse in endurance sports, and has been forbidden by the World Anti-Doping Agency since 1989[8].…”

Section: Introductionmentioning

confidence: 99%

Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin

et al. 2014

View full text Add to dashboard Cite

Recombinant human erythropoietin (rhEPO) has been extensively used as pharmaceutical product for treatment of anemia. Glycosylation of rhEPO affects the biological activity, immunogenicity, pharmacokinetics and in vivo clearance rate of rhEPO. Characterization of the glycosylation status of rhEPO is of great importance for its quality control. In this study, we established a fast and comprehensive approach for reliable characterization and relative quantitation of rhEPO glycosylation, which combines multiple enzyme digestion, hydrophilic interaction chromatography (HILIC) enrichment of glycopeptides, and tandem mass spectrometry (MS) analysis. The N-linked and O-linked intact glycopeptides were analyzed with high resolution and high accuracy (HR/AM) mass spectrometry on an Orbitrap. Totally, 74 intact glycopeptides from four glycosylation sites at N24, N38, N83 and O126 were identified with the simultaneous determination of peptide sequences and glycoform compositions. The extracted ion chromatograms based on the HR/AM data allowed relative quantification of glycoforms. Our results could be extended to the quality control of rhEPO or help to establish detection approaches for glycosylation of other proteins.

show abstract

Section: Introductionmentioning

confidence: 99%

Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Other beneficial effects of EPO appear to be related to the proangiogenic properties on endothelial cells, which could be useful in the treatment of ischemic heart disease. Such kind of findings indicates that EPO in addition to anemia correction could provide potential therapeutic benefits in the management of cardiovascular diseases [33].…”

Section: Erythropoietin: a Major Regulator Of Ex Vivo Rbc Production mentioning

confidence: 92%

“…Its amino acid sequence first mapped out in 1983 has a stimulating effect on bone marrow erythroid precursors. It has been demonstrated through structural studies of human EPO that it is a single polypeptide of 30.4 kD with 193 amino acids residues which are folded into four -helices and contain two disulphide bridges between cysteines (6-161 and [29][30][31][32][33]. EPO is also a structure homologue of growth hormone and other members of the hematopoietic class 1 cytokine super family [26].…”

Section: Erythropoietin: a Major Regulator Of Ex Vivo Rbc Production mentioning

confidence: 99%

Role of Erythropoietin and Other Growth Factors inEx VivoErythropoiesis

Singh

Saini

Chandra

2014

Advances in Regenerative Medicine

View full text Add to dashboard Cite

Erythropoiesis is a vital process governed through various factors. There is extreme unavailability of suitable donor due to rare phenotypic blood groups and other related complications like hemoglobinopathies, polytransfusion patients, and polyimmunization. Looking at the worldwide scarcity of blood, especially in low income countries and the battlefield, mimicking erythropoiesis usingex vivomethods can provide an efficient answer to various problems associated with present donor derived blood supply system. Fortunately, there are manyex vivoerythropoiesis methodologies being developed by various research groups using stem cells as the major source material for large scale blood production. Most of theseex vivoprotocols use a cocktail of similar growth factors under overlapping growth conditions. Erythropoietin (EPO) is a key regulator in mostex vivoprotocols along with other growth factors such as SCF, IL-3, IGF-1, and Flt-3. Now transfusable units of blood can be produced by using these protocols with their set of own limitations. The present paper focuses on the molecular mechanism and significance of various growth factors in these protocols that shall remain helpful for large scale production.

show abstract

“…In vitro, EPO has a protective effect in hyperglycemia, when it maintains Wnt1 protein expression required for proliferation and survival of neurons, cardiomyocytes, erythrocytes, endothelial and adipose cells; it prevents DNA degradation, and maintains mitochondrial membrane potential. Its cytoprotective effect is realized through NF-kB, which attaches itself to DNA, activating transcription of genes inhibiting apoptosis proteins (Baksheev and Kolomoec 2008, Maiese 2009, Raddino et al 2008.…”

Section: Erythropoietin (Epo)mentioning

confidence: 99%

Pharmacological modulation of cell functional activity with valproic acid and erythropoietin

Golubinskaya¹,

Sarycheva²,

Burda³

et al. 2019

RRP

View full text Add to dashboard Cite

Introduction: Valproic acid (VA) is carboxylic acid with a branched chain, which is used as an antiepileptic drug. Valproic acid influence on cells in vivo: VA, which is an antiepileptic drug, is also a teratogen, which causes defects of a neural tube and an axial skeleton, although the mechanisms are not yet fully clear. Valproic acid influence on mesenchymal stem cells (MSC) in vitro: It is shown that valproic acid reduces the intracellular level of oxygen active forms. Valproic acid effect on tumor cells: VA inhibits tumor growth through several mechanisms, including the cell cycle stop, differentiation induction and inhibition of growth of tumor vessels. Valproic acid influence on enzymes: It affects mainly GSK-3. Valproic acid influence on animals’ cells: It is shown that VA can significantly improve an ability to develop in vitro and improve nuclear reprogramming of embryos. Erythropoietin (EPO): Is an hypoxia-induced hormone and a cytokine, which is necessary for normal erythropoiesis. EPO is widely used in in vitro experiments. Conclusion: Thus, the influence of VA and EPO on cells can be used in cell technologies.

show abstract

Erythropoietin: a new perspective in cardiovascular therapy

Cited by 5 publications

References 13 publications

Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin

Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin

Role of Erythropoietin and Other Growth Factors inEx VivoErythropoiesis

Pharmacological modulation of cell functional activity with valproic acid and erythropoietin

Contact Info

Product

Resources

About